RecruitingPhase 2NCT07030699
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Studying Indolent B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Pallawi Torka, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Epcoritamab(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
Collaborators
Genmab · Incyte Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07030699 on ClinicalTrials.govOther trials for Indolent B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07166419Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT06824701Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaUniversity of Utah
- RECRUITINGPHASE3NCT07029217A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06458439Epcoritamab-CAR T Cells for Large B-cell LymphomasAbramson Cancer Center at Penn Medicine
- RECRUITINGPHASE2NCT06442475Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06386315Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin LymphomaMayo Clinic
- RECRUITINGPHASE2NCT06350318Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasH. Lee Moffitt Cancer Center and Research Institute